Pharmaceutical Dova Pharmaceuticals, which was acquired by Swedish Orphan Biovitrum last year, today announced Doptelet (avatrombopag) has been granted approval from the China National Medical Products Administration (NMPA) for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure (ie, the CLD indication). 30 April 2020